Captor Therapeutics ® Investor Relations

      Investor Relations

      A shareholder’s request to include certain matters on the agenda of the Ordinary General Meeting called for 29 June 2021

      Publication date: 2021-06-08
      Number: RB ESPI 15/2021

      Current report no. 15/2021

      Date of preparation: 8 June 2021

      Subject: A shareholder’s request to include certain matters on the agenda of the Ordinary General Meeting called for 29 June 2021

      Legal basis: Article 56 sec. 1 point 2 of the Public Offering Act - current and periodical information

      The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the “Company”) informs that on 8 June 2021 it received from a shareholder of the Company, Mr. Paweł Holstinghausen Holsten, a request to include in the agenda of the Ordinary General Meeting of the Company called for 29 June 2021, the following point of the agenda:

      “Adoption of a resolution to grant a member of the Supervisory Board of the Company the right to subscribe for the Company’s shares under the Company’s employee incentive scheme based on shares of the Company”.

      In view of the foregoing the Company presents below the amended agenda of the Ordinary General Meeting called for 29 June 2021:

      1. Opening of the Ordinary General Meeting.
      2. Appointment of the Chairman of the Ordinary General Meeting.
      3. Ascertaining that the Ordinary General Meeting was duly called and is able to pass binding resolutions.
      4. Adoption of the agenda of the Ordinary General Meeting.
      5. Presentation of financial results of the Company and the Capital Group of Captor Therapeutics S.A.
      6. Presentation of the report of the Supervisory Board for 2020
      7. Review of the separate financial statement of Captor Therapeutics S.A. for 2020 and adoption of a resolution to approve it.
      8. Review of the consolidated financial statement of the Capital Group of Captor Therapeutics S.A. for 2020 and adoption of a resolution to approve it.
      9. Review of the report of the Management Board on operations of Captor Therapeutics S.A. and the Capital Group of Captor Therapeutics S.A. for the period between 1 January and 31 December 2020, included in the annual report of the Capital Group of Captor Therapeutics S.A., and adoption of a resolution to approve it.
      10. Adoption of a resolution to cover a net loss for the fiscal year 2020.
      11. Adoption of resolutions to grant a discharge to all Members of the Management Board of the Company who served in the fiscal year 2020.
      12. Adoption of resolutions to grant a discharge to all Members of the Supervisory Board of the Company who served in fiscal year 2020.
      13. Adoption of a resolution to amend the Articles of Association of Captor Therapeutics S.A., in particular through the revocation of the existing Articles of Association and adoption of a new Articles of Association in full.
      14. Adoption of a resolution to grant a member of the Supervisory Board of the Company the right to subscribe for the Company’s shares under the Company’s employee incentive scheme based on shares of the Company.
      15. Closing of the Ordinary General Meeting

      Point 14 was added to the initial agenda: “Adoption of a resolution to grant a member of the Supervisory Board of the Company the right to subscribe for the Company’s shares under the Company’s employee incentive scheme based on shares of the Company”. The shareholder’s request constitutes Appendix no. 1 to this report. Along with the request, the shareholder submitted a draft resolution of the Ordinary General Meeting concerning the above-mentioned matter which constitutes Appendix no. 2 to this report.


      Attachments: